Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?

Diabetes Obes Metab. 2017 Jun;19(6):909-911. doi: 10.1111/dom.12897. Epub 2017 Mar 8.

Authors

Edison Goncalves¹, David S H Bell²

Affiliations

¹ Diabetes and Thyroid Associates, Birmingham, Alabama.
² Southside Endocrinology, Birmingham, Alabama.

PMID: 28176440
DOI: 10.1111/dom.12897

No abstract available

Publication types

Comparative Study
Letter

MeSH terms

Aged
Benzhydryl Compounds / administration & dosage*
Canagliflozin / administration & dosage*
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / epidemiology
Drug Administration Schedule
Drug Therapy, Combination / methods
Female
Glucagon-Like Peptide-1 Receptor / agonists*
Glucosides / administration & dosage*
Humans
Hypoglycemic Agents / administration & dosage*
Liraglutide / administration & dosage*
Male
Middle Aged
Retrospective Studies
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors*
Treatment Outcome

Substances

Benzhydryl Compounds
Glucagon-Like Peptide-1 Receptor
Glucosides
Hypoglycemic Agents
SLC5A2 protein, human
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors
Canagliflozin
Liraglutide
empagliflozin